5 result(s) displayed (1 - 5 of 5):

Roche and Genentech's first post-merger setback (from Corporate Dealmaker)

Now a wholly owned division of Roche Holding AG (SWX:ROG), Genentech Inc. (NYSE:DNA) said late Wednesday, April 8, it would withdraw its psoriasis drug Raptiva from the U.S. market because of the threat of a deadly brain infection.The news is the first post-merger setback for Roche, which consummated late...

Posted on April 8, 2009 5:20 PM

Mylan to acquire rest of Matrix Laboratories (from Corporate Dealmaker)

U.S. generic and specialty pharmaceutical company, Mylan Inc. (NASDAQ:MYL), acquired a 71.5% stake in India's Matrix Laboratories Ltd. for $736 million in 2006. Now Mylan wants the rest and will pay 150 rupees per share (a total of $133 million), which is a 27% premium to Matrix's March 26 closing...

Posted on March 26, 2009 2:05 PM

Amgen gets smaller--again (from Corporate Dealmaker)

Amgen Inc. used to be the acquirer. Now it's the seller. In the latest sign of the times, Amgen said Thursday, it would sell the rights to a clinical-stage painkiller to Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals Inc. for $50 million. That's immediate cash in hand -- something Amgen could...

Posted on August 1, 2008 12:51 PM

For pharma, a nongeneric problem in corporate development (from Corporate Dealmaker)

All corporate dealmakers face challenges that are more or less unique to their industries. But it's hard to think of a set of corp dev choices as industry-specific--and as stark--as those in the pharma world. Yesterday the patent for Fosomax...

Posted on February 7, 2008 9:05 AM

Defending against defections (from Corporate Dealmaker)

Importers may find they face significant liabilities, but the right contractual provisions can mitigate your company's risks.

Posted on October 15, 2007 9:11 AM